CIK 0001638287
- Non-accelerated filer
- Smaller reporting company
MetaVia Inc.
Sign in to watch- Ticker
- MTVA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472389984
- Phone
- +1 857-702-9600
- Business address
- 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE, MA, 02138
- Former names
- NeuroBo Pharmaceuticals, Inc., Gemphire Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 19 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-07-24 | KOUSKY KENNETH W Director | Grant or award | +15,000 | 26,935 | ||
| 2019-07-24 | Reno Seth Chief Commercial Officer | Grant or award | +100,000 | 118,286 | ||
| 2019-07-24 | Bisgaier Charles PhD Chief Scientific Off. & Chair | Grant or award | +100,000 | 1,348,914 | ||
| 2019-07-24 | Gullans Steven R. Ph.D. President & CEO | Grant or award | +300,000 | 300,000 | ||
| 2018-05-22 | Gullans Steven R. Ph.D. President & CEO | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2018-05-22 | Gullans Steven R. Ph.D. President & CEO | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2018-05-01 | Gullans Steven R. Ph.D. President & CEO | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2018-02-08 | Reno Seth Chief Commercial Officer | Purchase | +14,286 | $7.00 | $100K | 18,286 |
| 2018-02-08 | Gullans Steven R. Ph.D. Interim President & CEO | Purchase | +71,429 | $7.00 | $500K | 930,252 |
| 2018-01-29 | SASSINE ANDY Director | Grant or award · Stock Option (right to buy) | +10,800 | 10,800 | ||
| 2018-01-29 | LICHTINGER PEDRO Director | Grant or award · Stock Option(right to buy) | +10,800 | 10,800 | ||
| 2018-01-29 | KOUSKY KENNETH W Director | Grant or award · Stock Option (right to buy) | +10,800 | 10,800 | ||
| 2018-01-29 | Hawryluk P. Kent Director | Grant or award · Stock Option (right to buy) | +10,800 | 10,800 | ||
| 2018-01-29 | Gullans Steven R. Ph.D. Interim President & CEO | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2018-01-28 | Bisgaier Charles PhD Chief Scien Officer & Chair | Grant or award · Stock Option (right to buy) | +48,000 | 48,000 | ||
| 2018-01-28 | Golden Lee Scott Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +148,000 | 148,000 | ||
| 2018-01-28 | MATHIESEN JEFFREY S Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +48,000 | 48,000 | ||
| 2018-01-28 | Reno Seth Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +48,000 | 48,000 | ||
| 2017-08-14 | MATHIESEN JEFFREY S Chief Financial Officer | Option exercise | +3,207 | $3.59 | $12K | 14,134 |
| 2017-08-14 | MATHIESEN JEFFREY S Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −3,207 | 0 |
Page 5 of 7 · 135 trades